Vikram Purohit
Stock Analyst at Morgan Stanley
(0.78)
# 3,807
Out of 4,862 analysts
168
Total ratings
28.57%
Success rate
-15.52%
Average return
Main Sectors:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics | Downgrades: Equal-Weight | $73 → $62 | $53.98 | +14.86% | 7 | May 14, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $170.78 | +46.39% | 19 | May 5, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Equal-Weight | $10 → $8 | $4.92 | +62.60% | 2 | Apr 10, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $67.73 | -4.03% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $104.13 | +82.46% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $10.33 | +238.82% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.35 | +106.90% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $22.82 | +35.85% | 2 | Sep 11, 2024 | |
| ABSI Absci | Initiates: Overweight | $7 | $2.78 | +151.80% | 1 | Jul 3, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $6.97 | +129.56% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $4.39 | +583.37% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $22 | $6.70 | +228.36% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $13.43 | -25.54% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $2.56 | +134.38% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $9.27 | +353.07% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $23 | $1.43 | +1,473.43% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $46.88 | -12.54% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $34.23 | +16.86% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $0.84 | +1,450.20% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $21.43 | +77.32% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $11.01 | +81.74% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $10.69 | -6.45% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $7 | $29.54 | -76.30% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.55 | +1,319.35% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $9.10 | +119.78% | 2 | Aug 5, 2020 |
Halozyme Therapeutics
May 14, 2025
Downgrades: Equal-Weight
Price Target: $73 → $62
Current: $53.98
Upside: +14.86%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $170.78
Upside: +46.39%
Recursion Pharmaceuticals
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $4.92
Upside: +62.60%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $67.73
Upside: -4.03%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $104.13
Upside: +82.46%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $10.33
Upside: +238.82%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.35
Upside: +106.90%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $22.82
Upside: +35.85%
Absci
Jul 3, 2024
Initiates: Overweight
Price Target: $7
Current: $2.78
Upside: +151.80%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $6.97
Upside: +129.56%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $4.39
Upside: +583.37%
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $6.70
Upside: +228.36%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $13.43
Upside: -25.54%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $2.56
Upside: +134.38%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $9.27
Upside: +353.07%
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $1.43
Upside: +1,473.43%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $46.88
Upside: -12.54%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $34.23
Upside: +16.86%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $0.84
Upside: +1,450.20%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $21.43
Upside: +77.32%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $11.01
Upside: +81.74%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $10.69
Upside: -6.45%
Dec 10, 2021
Downgrades: Underweight
Price Target: $18 → $7
Current: $29.54
Upside: -76.30%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.55
Upside: +1,319.35%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $9.10
Upside: +119.78%